Imatinib for Multiple Sclerosis (MS) Relapses

July 30, 2021 updated by: Tomas Olsson

Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study

To investigate if treatment with Imatinib results in a better outcome than standard care in form of Methylprednisolone(MP) after MS-associated relapses.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Hamburg, Germany, 20246
        • Recruiting
        • Hamburg-Eppendorf
        • Contact:
        • Principal Investigator:
          • Christoph Heesen
      • Kiel, Germany, 24105
      • Köln, Germany, 50937
      • Bergen, Norway, 5021
      • Lørenskog, Norway, 1478
      • Oslo, Norway, 0372
      • Oslo, Norway, 0424
        • Not yet recruiting
        • Ullevåls sjukhus
        • Contact:
      • Göteborg, Sweden, 41345
      • Linköping, Sweden, 58185
      • Stockholm, Sweden, 11341
        • Recruiting
        • Akademiskt specialistcentrum
        • Contact:
      • Stockholm, Sweden, 17176
        • Recruiting
        • Karolinska Universitetssjukhuset, Solna
        • Contact:
      • Uppsala, Sweden, 75185
    • Stockholm
      • Huddinge, Stockholm, Sweden, 14186
        • Recruiting
        • Karolinska Universityhospital, Huddinge
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • An acute exacerbation, relapse, in persons with RRMS, either newly diagnosis or on treatment with one of the long-term immunomodulatory drugs, or possible MS where the diagnosis is supported by typical MRI or cerebrospinal fluid changes typical of MS (this enables inclusion of persons with a first neuroinflammatory bout, with high risk of developing MS before fulfilling the McDonald criteria for definite MS, or high risk for developing MS in the category clinically isolated syndrome (CIS)/possible MS with supporting MRI lesions and/or cerebrospinal fluid aberrations suggesting intra-thecal immunoglobulin synthesis with oligoclonal bands/and/or increased free Kappa Light chains. The relapse should be deemed to require relapse treatment by the investigator and affect a functional domain with a minimum of grade 2.
  • 18-55 years of age
  • Affection of any of the following EDSS sub-domains representing the targeted neurological deficit: 1. Visual function. grade 0-6, 2. Brain stem function grade 0-5. 3. Pyramidal function, grade 0-6. 4. Cerebellar function, grade 0-5. 5. Sensory function grade 0-6, and deterioration at least one step in any of these EDSS domains
  • EDSS ≤ 6 before the acute exacerbation
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, if they are using effective methods of contraception during the study. Acceptable birth control methods are those with a failure rate of less than 1% per year when used consistently and correctly according to CTFG, September 2014 "Recommendations related to contraception and pregnancy testing in clinical trials". Such methods include:

    1. Combined (estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation.

      • oral
      • intravaginal
      • transdermal
    2. progestogen-only hormonal contraception associated with inhibition of ovulation

      • oral
      • injectable
      • implantable
    3. intrauterine device (IUD)
    4. intrauterine hormone-releasing system (IUS)
    5. bilateral tubal occlusion
    6. total abstinence or vasectomized partner.

Exclusion Criteria:

  • A pseudo-relapse should be excluded, as deemed by the experienced treating neurologist, and as evidenced by an active infection, likely with fever, with reappearing new signs and symptoms in a previously affected neurological function.
  • Inability to provide informed consent
  • Concomitant medication with drugs which may increase the plasma concentration of Imatinib - ketoconazole, itraconazole , erythromycin and clarithromycin
  • Concomitant medication with drugs which may decrease the plasma concentration of Imatinib: dexamethasone, phenytoin, carbamazepin, rifampicin, phenobarbital, fosphenytoin, primidon, Hypericum perforatum (St John's wort).
  • Female patients with childbearing potential, if pregnancy cannot be excluded by pregnancy test (urine point-of-care pregnancy test).
  • Patient is participating in other interventional study
  • General infection or any other condition judged by the treating neurologist to contra-indicate Imatinib
  • Any laboratory deviation of general bodily functions such as kidney, or renal function judged to be of clinical significance by the treating neurologist constitutes an exclusion criteria.
  • Patients with a positive Hepatitis B-DNA test result or serology indicating latent infection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Imatinib
Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.
Tablets 400 mg
Active Comparator: Methylprednisolone
Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.
1 g tablets or infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional system score (FSS) change in the most worsened FSS after 28 days due to the acute relapse
Time Frame: 28 days
The primary endpoint is mean change between baseline and day 28 in the most worsened FSS due to the acute relapse comparing MP and Imatinib. In case more than one domain is affected, priority of selected FSS should be in the following order: 1) Pyramidal, 2) Brain stem, 3) Cerebellar, 4) Visual, 5) Sensory. At least a two step deterioration due to neuroinflammatory bout should have occurred. Bowel and Cerebral domains will not be considered in the primary endpoints. The FSS is graded accordingly: 1. Visual function. Grade 0-6 2. Brain stem function grade 0-5 3. Pyramidal function, grade 0-6 4. Cerebellar function, grade 0-5 5. Sensory function grade 0-6 6. bowel/bladder function 7. Cerebral functions
28 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional system score (FSS) change between baseline and week 12 in the most worsened FSS due to the acute relapse
Time Frame: 12 weeks
In case more than one domain is affected, priority of selected FSS should be in the following order: 1) Pyramidal, 2) Brain stem, 3) Cerebellar, 4) Visual, 5) Sensory. At least a two step deterioration due to neuroinflammatory bout should have occurred.
12 weeks
Mean expanded disability status scale (EDSS) change between baseline and day 28
Time Frame: 28 days
Calculation of EDSS summary score is based on the FSS score, from 0-5 with 0 representing normal neurological exam and 10 representing death by MS
28 days
Mean change in 9-hole peg test (evaluates upper limb function) between baseline and day 28
Time Frame: 28 days
Evaluates upper limb function
28 days
Mean change in timed 25- walk between baseline and day 28
Time Frame: 28 days
28 days
Mean change in symbol digital modality test (SDMT) between baseline and day 28
Time Frame: 28 days
Evaluates cognitive function, with a score range of 0 to 110, with 110 representing the best cognitive function
28 days
Mean change in Multiple Sclerosis Impact Scale (MSIS-29; MS-specific quality of life (QoL) scale) between baseline and day 28
Time Frame: 28 days
The MISIS-29 consists of 29 items (composed of 20- item physical scale and a 9-item psychological scale), graded from 1-5 points with 5 indicating the most severe impact. The points for the two scales are individually summarized. The physical scale results in a sum with a range 20-100 , where 100 indicates the worse health. The psychological scale is similarly resulting in a range between to 9- 45, where 9 is the least and 45 is the worst.
28 days
Mean change in EQ5D (EuroQol 5 dimensions) (general QoL) between baseline and day 28.
Time Frame: 28 days
EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression
28 days
Any difference in number of new brain MRI lesions at day 14 with regards to the baseline, comparing the two drugs
Time Frame: 14 days
14 days
Any difference in number of new brain MRI lesions at day 28 with regards to the baseline, comparing the two drugs
Time Frame: 28 days
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Anticipated)

December 31, 2022

Study Completion (Anticipated)

July 30, 2023

Study Registration Dates

First Submitted

September 14, 2018

First Submitted That Met QC Criteria

September 14, 2018

First Posted (Actual)

September 17, 2018

Study Record Updates

Last Update Posted (Actual)

August 2, 2021

Last Update Submitted That Met QC Criteria

July 30, 2021

Last Verified

July 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on Imatinib Mesylate

3
Subscribe